文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

射血分数保留的心力衰竭中的微血管功能障碍:病理生理学、评估、患病率和预后

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.

作者信息

Bilak Joanna M, Alam Uazman, Miller Christopher A, McCann Gerry P, Arnold Jayanth R, Kanagala Prathap

机构信息

Department of Cardiovascular Sciences, University of Leicester and the Leicester NIHR Biomedical Research Centre, Glenfield Hospital Leicester, UK.

Liverpool University Hospitals NHS Foundation Trust Liverpool, UK.

出版信息

Card Fail Rev. 2022 Jul 1;8:e24. doi: 10.15420/cfr.2022.12. eCollection 2022 Jan.


DOI:10.15420/cfr.2022.12
PMID:35846985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9274364/
Abstract

Heart failure with preserved ejection fraction (HFpEF) currently accounts for approximately half of all new heart failure cases in the community. HFpEF is closely associated with chronic lifestyle-related diseases, such as obesity and type 2 diabetes, and clinical outcomes are worse in those with than without comorbidities. HFpEF is pathophysiologically distinct from heart failure with reduced ejection fraction, which may explain, in part, the disparity of treatment options available between the two heart failure phenotypes. The mechanisms underlying HFpEF are complex, with coronary microvascular dysfunction (MVD) being proposed as a potential key driver in its pathophysiology. In this review, the authors highlight the evidence implicating MVD in HFpEF pathophysiology, the diagnostic approaches for identifying MVD (both invasive and non-invasive) and the prevalence and prognostic significance of MVD.

摘要

射血分数保留的心力衰竭(HFpEF)目前约占社区所有新发心力衰竭病例的一半。HFpEF与慢性生活方式相关疾病密切相关,如肥胖和2型糖尿病,合并症患者的临床结局比无合并症患者更差。HFpEF在病理生理上与射血分数降低的心力衰竭不同,这在一定程度上可以解释两种心力衰竭表型之间可用治疗方案的差异。HFpEF的潜在机制很复杂,冠状动脉微血管功能障碍(MVD)被认为是其病理生理学中的一个潜在关键驱动因素。在这篇综述中,作者强调了MVD在HFpEF病理生理学中的证据、识别MVD的诊断方法(包括有创和无创)以及MVD的患病率和预后意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f214/9274364/85e29f8aa6d2/cfr-08-e24-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f214/9274364/85e29f8aa6d2/cfr-08-e24-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f214/9274364/85e29f8aa6d2/cfr-08-e24-g001.jpg

相似文献

[1]
Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis.

Card Fail Rev. 2022-7-1

[2]
Prevalence and Prognostic Significance of Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.

JACC Cardiovasc Imaging. 2022-6

[3]
Microvascular dysfunction in patients with heart failure with preserved ejection fraction: A meta-analysis.

Microcirculation. 2023-10

[4]
The Role of Systemic Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction.

Biomolecules. 2022-2-9

[5]
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.

J Am Coll Cardiol. 2013-5-15

[6]
Long-term outcomes prediction in diabetic heart failure with preserved ejection fraction by cardiac MRI.

Eur Radiol. 2024-9

[7]
Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.

Circulation. 2015-2-10

[8]
Recent advances in mechanistic studies of heart failure with preserved ejection fraction and its comorbidities-Role of microRNAs.

Eur J Clin Invest. 2024-3

[9]
The Molecular and Cellular Mechanisms Associated with a Microvascular Inflammation in the Pathogenesis of Heart Failure with Preserved Ejection Fraction.

Acta Naturae. 2020

[10]
Microvascular endothelial dysfunction in skin is associated with higher risk of heart failure with preserved ejection fraction in women with type 2 diabetes: the Hoorn Diabetes Care System Cohort.

Cardiovasc Diabetol. 2023-9-1

引用本文的文献

[1]
The Hidden Price of Plenty: Oxidative Stress and Calorie-Induced Cardiometabolic Dysfunction.

Life (Basel). 2025-6-27

[2]
Targeted Overexpression of Mitochondrial ALDH2 in Coronary Endothelial Cells Mitigates HFpEF in a Diabetic Mouse Model.

Biomolecules. 2025-7-16

[3]
Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment.

Cardiovasc Diabetol. 2025-7-3

[4]
Coronary microvascular dysfunction and its role in heart failure with preserved ejection fraction for future prevention and treatment.

Am J Prev Cardiol. 2025-3-29

[5]
Heart failure and microvascular dysfunction: an in-depth review of mechanisms, diagnostic strategies, and innovative therapies.

Ann Med Surg (Lond). 2024-12-24

[6]
Abnormal skeletal muscle and myocardial vasoreactivity manifests prior to heart failure in a diabetic cardiomyopathy rat model.

Discov Med (Cham). 2025

[7]
Heart failure with preserved ejection fraction.

Nat Rev Dis Primers. 2024-8-14

[8]
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.

Card Fail Rev. 2024-4-3

[9]
Physiology and functional significance of the coronary microcirculation: An overview of its implications in health and disease.

Am Heart J Plus. 2024-3-8

[10]
Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis.

ESC Heart Fail. 2024-8

本文引用的文献

[1]
Prevalence and Prognostic Significance of Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.

JACC Cardiovasc Imaging. 2022-6

[2]
Invasive Assessment of Coronary Microvascular Function.

J Clin Med. 2021-12-31

[3]
The 'Ten Commandments' of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

Eur Heart J. 2022-2-10

[4]
Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction.

J Cardiovasc Magn Reson. 2021-10-18

[5]
Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction.

Eur Heart J. 2021-11-14

[6]
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

N Engl J Med. 2021-10-14

[7]
Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction.

JAMA Cardiol. 2021-10-1

[8]
Cardiovascular and systemic determinants of exercise capacity in people with type 2 diabetes mellitus.

Ther Adv Endocrinol Metab. 2021-1-27

[9]
Atrial Fibrillation and Heart Failure: Epidemiology, Pathophysiology, Prognosis, and Management.

Card Electrophysiol Clin. 2021-3

[10]
Role of comorbidities in heart failure prognosis Part I: Anaemia, iron deficiency, diabetes, atrial fibrillation.

Eur J Prev Cardiol. 2020-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索